Neuroimaging of Adult-Type Diffuse Gliomas
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 15 August 2026 | Viewed by 8
Special Issue Editor
2. Department of Clinical Brain Sciences, Graduate School of Medicine, Gifu University, Gifu 501-1194, Japan
Interests: brain tumor; glioma; surgery; pathology; PET
Special Issue Information
Dear Colleagues,
Molecular diagnosis was introduced in the 2016 World Health Organization (WHO) Classification of tumors of the central nervous system for the diagnosis of glioma. In the 2021 revision of the WHO classification, adult-type diffuse glioma was categorized according to IDH status and the presence or absence of 1p/19q co-deletion into three types: astrocytoma, IDH-mutant; oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and glioblastoma, IDH-wildtype.
Compared with the former two entities, the latter—IDH-wild—remains incurable despite multimodal treatment, and long-term survival outcomes are poor. Notably, there are cases in which tumors lacking contrast enhancement on MRI are nonetheless molecularly diagnosed as IDH-wildtype. If early therapeutic intervention can be initiated based on imaging approaches capable of identifying IDH-wildtype status even at the non-contrast stage, improved prognostic outcomes may be achievable. Consequently, imaging research related to the molecular diagnosis of glioma is of substantial clinical importance.
In this Special Issue, we seek the latest findings in imaging-based diagnosis relevant to the molecular classification of adult-type diffuse gliomas, as well as studies that propose future research directions in this field.
Dr. Hirohito Yano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioma
- image diagnosis
- molecular diagnosis
- MRI
- MRS
- SPECT
- PET
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
